TECH · Bio-Techne Corp
Price
Snapshot
50 fields · last close| Market Cap | $11.38B |
| P/E | 62.58 |
| Float | 155.3M |
| Beta | 1.28 |
| Volatility | 32.1% |
| Exchange | NASDAQ |
| Sector | Life Sciences Tools & Services |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 76.2 |
| Price | 72.50 |
| Change | −0.10% |
| Prev Close | 72.57 |
| Open | 72.59 |
| Day Low | 72.45 |
| Day High | 72.59 |
| Avg Vol | 3 |
| Avg $ Vol | $197.3M |
| 52W High | 72.69 |
| 52W Low | 43.20 |
| 52W Pos | 99.4% |
| From High | −0.26% |
| From Low | +67.82% |
| Max DD 1Y | −39.33% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +0.00% |
| SMA 50 | +0.16% |
| SMA 200 | +15.60% |
| RSI (14) | 58.2 |
| Vol 30D | 2.0% |
| Vol 90D | 35.1% |
| 1Y Range | 43–73 |
| Daily bars | 537 |
| Perf Week | +0.15% |
| Perf Month | +0.22% |
| Perf Quarter | +1.30% |
| Perf Half Y | +19.79% |
| Perf Year | +17.81% |
| Perf YTD | +21.54% |
| Prev Day | −0.10% |
| Clavix | B |
| Debt / Eq | 0.09 |
| Curr Ratio | 4.55 |
| Int Cover | 27.7× |
| FCF Margin | 21.7% |
| Rev Growth | −0.4% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 7 / 19 |
What TECH does
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.
The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications.
The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.
Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Clavix risk grade
regraded every trading dayTECH grades B, 76.2 of 100. Steadiest on News Sentiment (69), most exposed on Price Stability (61, mixed). 2 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 7 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| TECH | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.28 | 1.18 |
| Volatilityannualized | 32.1% | 29.4% |
| Max drawdown, past yearworst peak-to-trough fall | −39.3% | — |
| Typical daily movemedian absolute daily change | 0.86% | — |
| Days beyond ±3%of the last 252 sessions | 43 (17%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| TECH | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.28 | 1.18 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Moderate 53% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| TECH | |
|---|---|
| 1 week | +0.2% |
| 1 month | +0.2% |
| Year to date | +21.5% |
| 1 year | +17.8% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| TECH | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 2 Jul |
| Average score0 most bearish, 100 most bullish | 58 |
| Bullish · bearisharticles above 60 · below 40 | 19 · 6 |
| Directionarticles whose tone is improving vs worsening | 19 ↑ 6 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| TECH | |
|---|---|
| Revenue growthyear over year | −0.4% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openBio-Techne Corporation has opened a new manufacturing facility in Bristol, UK, dedicated to producing small molecules that meet GMP (Good Manufacturing Practice) quality standards used in clinical and commercial drug production.
Bio-Techne opened a new manufacturing facility in Bristol, UK dedicated to producing small molecules that meet Good Manufacturing Practice (GMP) standards, which are the quality rules regulators require for materials used in cell therapies.
Bio-Techne opened a new manufacturing facility in Bristol, UK, dedicated to producing GMP-grade small molecules to support cell therapy developers.
Bio-Techne shareholders voted on September 23 to approve Merck KGaA's acquisition at $73 per share in cash, valuing the deal at about $11.3 billion including debt. In an unusual pairing, shareholders also voted down the executive pay package tied to the deal.
Bio-Techne shareholders approved the company's proposed acquisition by Merck KGaA at a special meeting on September 23, 2026, and the U.S. antitrust waiting period expired on September 18. Closing is expected by late 2026 or early 2027, pending remaining regulatory approvals and customary conditions.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| RGEN | Repligen Corp | B- | $11.14B | 268.12 | 1.14 | Compare |
| AVTR | Avantor Inc | B- | $11.11B | — | 0.97 | Compare |
| TEM | Tempus AI Inc | D- | $11.68B | — | 2.37 | Compare |
| QGEN | Qiagen NV | B+ | $9.51B | 23.22 | 0.59 | Compare |
| TXG | 10X Genomics Inc | C- | $9.10B | — | 2.02 | Compare |
| CRL | Charles River Laboratories International Inc | B- | $14.33B | — | 1.37 | Compare |
| BRKR | Bruker Corp | C | $8.35B | — | 1.26 | Compare |
| RVTY | Revvity Inc | B | $17.03B | 71.70 | 1.09 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.